The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies - Tian, Guangming; Zhao, Xinliang; Nie, Jun; Dai, Ling; Hu, Weiheng; Zhang, Jie; Chen, Xiaoling; Han, Jindi; Ma, Xiangjuan; Wu, Di; Han, Sen; Long, Jieran; et al. (Journal of Thoracic Disease, 2022)